“…Moreover, there were 43 studies with 11412 cases and 13936 controls for PON1-Q192R polymorphism (Table 1), and, for PON1 L55M polymorphism, 28 studies involved a total of 8565 cases and 9996 controls (Table 2). For PON1 Q192R polymorphism, a total of 8 cancer types were processed, including breast cancer [21, 27, 31, 32, 37, 39, 50], prostate cancer [22, 23, 40, 41], gastrointestinal cancer [19, 20, 48, 59, 60], hematologic tumor [25, 29, 33, 44], lung cancer [11, 12, 54], brain tumors [30, 35, 38, 45, 56, 57], ovarian cancer [34, 43] and other cancers [13, 26, 28, 42, 53, 58] (uterine leiomyoma, childhood embryonal tumors, metastatic gastric cancer, bladder cancer, and renal cell cancer). Besides, we disposed a total of 7 cancer types when dealing with PON1-L55M polymorphism nearly like PON1 Q192R polymorphism.…”